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INTRODUCTION
Uterine cervical cancer is the second most frequently diag-
nosed gynecologic malignancy in women worldwide (1) and
the fifth most common cancer among women after breast,
stomach, colon-rectum, and thyroid cancer in Korea (2). An
annual average incidence cases was about 4,360 composing
9.8% of all cancers in Korean women during 1999-2001 (2).
Cervical cancer was the most common female cancer in the
1980s, but subsequently, the proportion of cervical cancer
cases among all cancer cases in the Korea Central Cancer Reg-
istry reduced slightly. Moreover, a marked reduction in the
incidence of this tumor has been documented over the past
2 decades, and this has been largely attributed to widespread
screening and the early treatment of pre-invasive lesions (3-
5). However, no similar decreases have been reported in other
developed countries (6, 7).
The International Federation of Gynecology and Obstetrics
reported 5-yr recurrence and a 5-yr overall mortality rates
for cervical cancer of 28% and 27.8% respectively (8). The
widespread use of Papanicolaou (Pap) tests for cervical can-
cer screening has resulted in a dramatic decrease in cervical
cancer incidence and mortality over the several decades (9).
Screening tests for cervical cancer offer reliable methods of
reducing death from cervical cancer, despite the many pub-
lications that have documented above the low sensitivity of
these techniques. The Korean Society of Obstetrics and Gyne-
cology and the National Cancer Center have developed screen-
ing recommendations, and suggest that annual screening start
with sexual activity or at age 20 yr. The Korean Ministry of
Health and Welfare also developed a cervical cancer screening
program in 2001, in which they suggested biannual screen-
ing of women over 30 yr of age using the Pap. The Ameri-
can Cancer Society (ACS) has recently revised its screening
recommendations, and now suggests that screening start with-
in 3 yr of sexual activity or at age 21, and that it should be
less frequent than annually in women over 30 yr of age with
a history of 3 or more normal tests. In addition, co-testing
with human papillomavirus (HPV) and the discontinuance
of screening was endorsed in certain women (10). The Ameri-
can College of Obstetrics and Gynecologists (ACOG) has also
issued similar recommendations (11). However, despite nati-
onal screening guidelines, little is known about patterns of
obstetrician and gynecologist practices in this field.
The purpose of the present study was to characterize the
cervical cancer screening practices of obstetricians and gyne-
cologists in Korea.
MATERIALS AND METHODS
Study subjects
At May, 2005, about 900 obstetricians and gynecologists
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This study aimed to document current cervical cancer screening practices of physi-
cians in Korea. Questionnaires were distributed to 852 Korean obstetricians and
gynecologists, who attended the 91st Conference of the Korean Society of Obstet-
rics and Gynecology held during May, 2005. Questionnaires were returned by 30.6%
(260/852) of the recipients and 254 of these were eligible for analysis. Sixty-seven
percent started cervical cancer screening women at age 20, and 65% replied that
they would continue annual screening in a 35-yr-old woman with three consecutive
normal cytologic tests. Over 65% of respondents preferred conventional cytologic
screening to liquid-based cytology. The cost was a major determinant for selecting
screening method. Fifty-three percent used the human papillomavirus DNA test as
a triage for atypical squamous cells of undetermined significance. Our findings sug-
gest that majority of Korean obstetricians and gynecologists in hospital prefer annu-
al conventional cytologic testing to liquid-based cytology for financial reason. 
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attended the 91st Conference of the Korean Society of Obstet-
rics and Gynecology. Questionnaires were distributed to 852
physicians during the conference. Each physician received a
cover letter, a copy of questionnaire, and a return envelope
with postage paid. Authors also sent questionnaires to all con-
ference attendees absent from the conference two weeks after
the original distribution. Physicians were asked to complete
the survey and return them anonymously in a prepaid enve-
lope, with a reminder sent after two weeks to non-respon-
dents. 
Questionnaires
To perform this study, authors developed a questionnaire
containing 17 categorical questions to determine the attitudes
of Korean obstetricians and gynecologists regarding the cer-
vical cancer screening. Respondents were asked to discuss
major concerns and issues that they receive from patients
about cervical cancer screening. The questions used either
single- or multiple-choice responses. An introductory letter
requesting participation was enclosed, and a survey that could
be completed in 10 min or less was sought to encourage par-
ticipation. The questions were structured as clinical vignettes
on several subjects, including age to begin and end screening,
screening frequency, screening post-hysterectomy, pregnan-
cy screening, screening techniques being used, and concur-
rent HPV DNA testing. 
The questionnaire was prepared in 3 stages. First, the ques-
tions were selected based on discussions with 9 gynecologists
who perform gynecologic oncology service. The physicians
then reviewed the questionnaire and the wording. Questions
were revised for content and clarity. Finally, the survey ques-
tionnaire was field tested by 35 obstetricians and gynecolo-
gists who were either in the course of residency or fellowship
in Seoul National University Hospital.
Data analysis
Surveys were returned to one investigator and data was
abstracted and recorded by a research assistant. All question-
naires returned were given a sequential identification num-
ber. The questionnaires were hand-checked for completeness
and coded before data entry. The data were examined by sim-
ple frequency counts because the primary aim of current study
was to describe the attitudes and practices of physicians. Stu-
dent t test was used to compare the differences of the variables.
A p-value <0.05 was considered statistically significant.
RESULTS
Profile of participants
Of the 852 questionnaires distributed, 260 (30.6%) were
returned. After excluding questionnaires returned with more
than 8 questions unanswered (n=6). Two hundred and fifty-
four (29.8%) respondents were eligible; 158 (62.2%) were
male, 78 (30.7%) were female, and 18 (7.1%) did not sup-
ply information on gender. 
Table 1 and Fig. 1 show the characteristics of respondents.
Their mean (standard deviation) age was 40.3 (10.8) yr. The
majority of were male, and performed 1-15 Pap tests per
week. Table 2 summarizes patient’s age when respondents
began screening. The majority of respondents would screen
a 20-yr-old patient regardless of sexual activity (68.1% for
sexually active and 66.9% for not active respectively), and
79.9% of respondents would screen a 20-yr-old patient at
her first visit for antenatal care. Most respondents were reluc-
tant to perform cervical cancer screening in woman without
Characteristics Number %
Gender
Male 176 69.3
Female 78 30.7
Age (yr)
≤30 59 23.2
31-40 94 37.0
41-50 52 20.5
51-60 39 15.4
≥61 10 3.9
Professional position
Faculty, university hospital  86 33.9
Resident, university hospital 70 27.6
Faculty, general hospital 27 10.6
Resident, general hospital  28 11.0
Private practitioner 15 5.9
Others 28 11.0
Average Pap tests per week
≤15 119 46.9
16-30 56 22.0
≥31 79 31.1
Table 1. Characteristics of the 254 respondents
Question Yes, n (%) No, n (%)
A 20-yr-old woman who is not sexually  170  84 
active visits for her gynecologic examination.  (66.9) (33.1)
Will you recommend a Pap smear?
A 20-yr-old woman who became sexually  173 81 
active for one month ago visits for her first  (68.1) (31.9)
gynecologic examination. Will you recommend 
a Pap smear? 
A 35-yr-old woman who has never had  69  185
sexual intercourse presents for her first  (27.2) (72.8)
gynecologic visit. Will you recommend a 
Pap smear?  
A-20-yr-old woman who is 12 weeks  203 51
pregnant visits for her first antenatal care.  (79.9) (20.1)
Will you recommend a Pap smear?
Table 2. Age at cervical cancer screening commencement1056 H.H. Chung, J.W. Kim, S.-B. Kang
history of sexual intercourse, however, 27.2% of respondents
replied that they would screen 35-yr-old woman despite ab-
sence of sexual intercourse. 
Attitudes and reported practice for cervical cancer screen-
ing
Most respondents replied that they would screen patients
annually, and 57.1% that they would screen more frequently
if requested by a patient. The respondents’ answers on cervi-
cal cancer screening intervals after hysterectomy are portrayed
in Fig. 2. Most respondents would extend the screening inter-
val or cease screening in a woman with a history of hysterec-
tomy for a non-preinvasive lesion. Most respondents in the
current study preferred conventional cytologic screening me-
thod to liquid-based cystology (LBC) regardless of their pro-
fessional position and practice setting, and the Fig. 3 sum-
marizes the result. Fig. 4 shows that most (65.8%) respon-
dents preferred conventional cervical cytologic testing to LBC,
and the major determining factor was high cost. The reasons
for selecting screening method were different in these two
groups (p<0.001, Student t test). The attitudes of respondents
toward the ACS cervical cancer screening guidelines are list-
ed in Table 3. According to the table, the majority of respon-
dents (58.7%) agreed 2-yr screening interval using liquid-
based cytologic testing. However, if the option became avail-
able to combine screening with Pap and HPV DNA testing
every 3 yr, 33.9% would adopt this strategy, but 65.7% of
respondents would not adopt it despite negative results by
both Pap and HPV DNA testing. The respondents’ answers
on the strategy adopted in those with an abnormal cytology,
and on the preferred follow-up method are shown (Fig. 5).
%
100
80
60
40
20
0
1 yr ago  1 yr ago,  15 yr ago, Cervical
Myoma uteri Cervical dysplasia dysplasia
Reasons for hysterectomy
24 months
Fig. 2. Respondents’ intention of cervical cancer screening accor-
ding to reasons and duration after hysterectomy. Most respondents
replied they would screen annually a 55-yr-old woman with histo-
ry of cervical dysplasia, irrespective of the time of hysterectomy.
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Fig. 3. Proportion of physicians using liquid-based cytology (LBC,
black chart) and conventional cytology (CC, white chart) accord-
ing to professional position.
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Fig. 1. Characteristics of respondents. The majority of the respondents worked in university hospitals (A) located in Seoul and metropolitan
cities (B).
A B
University hospital
Seoul (capital)
Metropolitan city
Small 
downtown
Other
General hospital
Private clinic Public health facilityPreference of Annual Conventional Cervical Cancer Screening  1057
Most respondents (80.3%) replied that they use a HPV DNA
test and Pap for follow-up after a loop electrosurgical excision
procedure (LEEP) for preinvasive cervical lesions.
DISCUSSION
It is the first report on the screening preferences of Kore-
an obstetricians and gynecologists. Most respondents began
cervical cancer screening at age 20 yr, and screened annually
despite the recommendations of the ACS and ACOG, which
allow less frequent screening. This may be due to a higher
incidence of cervical cancer in Korea (18.4 per 100,000 in
Korea 1999-2001) (2) than in the United States (9.2 white
women per 100,000 in the U.S.A. 1996-2000) (1). 
Investigators have shown preference of continued-screening
in the U.S.A., but the proportion of respondents that replied
in this manner was a half of that of the present study. Sirovich
et al. (12) reported that 69% of their patient study popula-
tion would try to continue being screened annually even if
their doctors recommended less frequent screening and ad-
vised them of comparable benefits. Women should be reas-
sured about the low risk of developing cervical cancer with-
in short periods of time after a normal cytology result (13).
However, these women also should be aware of the risk of a
false positive result and of unnecessary invasive intervention
in low-risk women. 
LBC has been said to be more sensitive and specific than
conventional smears to diagnosis of cervical lesions (14-17).
Although pathologists prefer using LBC for reasons of screen-
ing accuracy, most practitioners in Korea use conventional
cytologic testing as a screening tool. In contrast, the majority
of physicians in the U.S.A. use LBC for sample collection (18,
19). The most common reason for using LBC in the U.S.A.
may be the ‘third-party pays system’, and the professional
liability system in the U.S.A. and the increasing number of
claims in the 1980s against pathologists for failure to diag-
nose cervical cancer on conventional Pap smears. However,
in Korea, the cost of screening using LBC is charged to pati-
ent, and government cover half for annual screening using
conventional cytology. Harkness et al. (20) reported that thin-
layer cytology yielded significantly fewer unsatisfactory results
and that is more sensitive at identifying cervical intraepithe-
lial neoplasia. On the contrary, a recent randomized trial show-
ed that the sensitivity of LBC is no greater than the sensitivity
of conventional cytology, and proposed careful consideration
on adopting LBC as a screening method cost especially in
Question
Yes, 
n (%)
No, 
n (%)
No
response,
n (%)
The American Cancer Society (ACS)  149 84 21
has recommended to screen with  (58.7) (33.1) (8.2)
liquid-based cytology per 2 yr
instead of annual Pap smear for 
cervical cancer screening. Would 
you adopt this recommendation in 
your practice? 
The American Cancer Society (ACS)  86 167 1
has recommended that women over  (33.9) (65.7) (0.4)
age 30 yr may be primarily screened 
with cytology plus a HPV DNA test. The 
ACS recommended that if both tests are 
negative, screening should not be 
performed again for 3 yr. This strategy
is an alternative to more frequent 
screening with cytology alone. Would 
you adopt this recommendation in 
your practice?
Table 3. Attitude toward the ACS recommendations for cervical
cancer screening
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Fig. 4. Reasons (white chart, cost; black chart, accuracy) for selec-
ting screening method among respondents (p<0.001, Student t
test). Over 90% of physicians who preferred liquid-based cytolo-
gy replied that they selected it for screening method due to higher
accuracy than conventional cytology. 
Fig. 5. Both HPV DNA testing and colposcopic examination are
equally favored as a screening triage for atypical squamous cells
of undetermined significance (ASCUS).
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low resource settings because of the higher cost (21). A large-
scale study of the accuracies and cost-effectiveness of the two
methods is warranted.
The ACS and ACOG recommend the discontinuation of
screening after removal of cervix in women without a history
of previous cervical disease (10, 11). Sirovich and Welch (22)
reported that two thirds of U.S.A. women who have under-
gone hysterectomy reported having had a Pap smear within
the past 3 yr despite 1996 recommendation from the U.S.A.
Preventive Services Task Force that routine Pap smear screen-
ing is unnecessary in women who have undergone a hysterec-
tomy for benign disease. However, the majority (74.2%) of
ACOG fellows responded that they would continue screen-
ing such women indefinitely, and the most common reason
given for this continuance concerning the adequate testing
of women older than 65 yr with a negative history (18). Most
respondents of current study are thought to be reluctant to
stop screening because there is no consensus or guideline as
to when to discontinue cervical cancer screening.
In the present study, about equal numbers of respondents
chose HPV DNA testing or colposcopy as next steps in cases
with ASCUS. However, Noller et al. (18) reported that most
ACOG fellows in the U.S.A. perform colposcopy after an AS-
CUS result. Moreover, the ASCUS-LSIL Triage Study (ALTS)
Group reported that HPV triage is at least as sensitive as im-
mediate colposcopy for detecting cervical intraepithelial neo-
plasia (CIN) grade 3 among women with ASCUS (23). ALTS
longitudinal data suggest that HPV triage is the most effec-
tive strategy for the management of women with ASCUS, as
was previously suggested by a cost-utility analysis based on
a model that closely approximated ALTS (24).
Authors did not include questions concerning the inten-
tions of simultaneous screening with a Pap test and HPV
DNA testing. Although cytologic screening programs using
Pap smears have dramatically reduced cervical cancer inci-
dence and mortality in developed nations, single Pap tests
have suboptimal sensitivities, limited reproducibilities, and
have produced many equivocal results (25, 26). Sherman et
al. (27) investigated combined Pap and HPV DNA testing
and concluded that both negative baseline tests were associ-
ated with a low risk of CIN3 or cancer during the following
45 months, largely because a negative HPV DNA test is asso-
ciated with a reduced risk of cervical neoplasia. They proposed
that negative combined testing would provide added reassur-
ance and allow screening interval lengthening among low-
risk women. As more physicians are introducing HPV DNA
testing in Korea, as case is being made to evaluate the effica-
cies of primary screening approaches with that of HPV DNA
testing via randomized clinical trials.
Current study has a number of limitations. First, the major-
ity of respondents worked at university hospitals, and their
responses may not be applicable to the private practice set-
ting, which are more commonly visited by women seeking
screening. Second, those who completed and returned the
questionnaire may not have been representative of Korean
obstetricians and gynecologists. The survey was given to phy-
sicians attending a conference, and a large number of the res-
pondents were undergoing residency training at university
hospitals, and that this may have influenced results. Third,
authors could not know the socioeconomic status of the pati-
ents being screened by the respondents in this study, which
also may have influenced the method of screening. Fourth,
the questionnaire contained no open questions, and thus ratio-
nales on debatable issues such as screening frequency and
triage after an abnormal Pap results were not available.
In summary, the majority of Korean obstetricians and gyne-
cologists in university or general hospital prefer annual cer-
vical cancer screening by using conventional cervical cyto-
logic testing for cost problem. A more systematic study to
assess the general practice pattern would be valuable for es-
tablishing nationwide screening strategy.
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